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The Joint United Nations Programme on HIV and AIDS recently 
reported that the number of people newly infected with HIV 
and the number of AIDS-related deaths are decreasing globally.1 
The programme reported that an estimated 2.6 million people 
were newly infected with HIV in 2009, representing a 20% drop 
from the 3.1 million people infected in 1999. In South Africa 
(SA), the estimated HIV prevalence among all age groups was 
10.6% (5.2 million people) in 2008.2 Although the prevalence 
in SA has stabilised in recent years, it is still significantly higher 
than in most countries in sub-Saharan Africa and the rest of 
the world. Studies have also reported a high prevalence of 
co-morbid depression among HIV-positive individuals (5 - 
48%).3-9 These variable rates of depression may be explained by 
variations in the actual populations studied (age, sex, education 
and ethnicity), different study designs, and differences in the 
stages of HIV/AIDS. 
Adherence refers to the willingness and ability of patients 
to follow health-related advice, take medication as prescribed, 
attend scheduled appointments, and complete recommended 
investigations. Actual adherence to treatment in most chronic 
diseases varies between 33% and 80%;10,11 however, the unique 
characteristics of HIV necessitate near-perfect adherence to 
antiretroviral therapy (ART).12-18 Reportedly, ART adherence 
rates of 90 - 100% are required to: ensure suppression of viral 
replication;12,19,20-22 maintain CD4 cell counts; prevent clinical 
progression to AIDS; and prevent the development of ART 
drug resistance and resistant HIV strains,10,23-28 which could 
leave drug-naive patients with few effective treatment options. 
Although debatable, other reports suggest that complete 
(100%) adherence is required to achieve optimal benefits and 
to prevent virus mutation to treatment-resistant strains.29-31 
Depression is reported to be one of the major risk factors 
affecting ART adherence in HIV-positive patients,32-35 
attributed to a passive36 or fatalistic-resigned coping style 
and hopelessness.37,38 ART adherence is lower in depressed 
HIV-positive individuals compared with non-depressed 
individuals. There are published data indicating that treatment 
for depression is associated with improved adherence.39,40 
However, there is not yet sufficient prospective evidence to 
support this.
This study, conducted in 2008 at the Perinatal HIV Research 
Unit (PHRU) of the University of the Witwatersrand, examined 
ART adherence in a group of HIV-positive patients with 
depression at Chris Hani Baragwanath Academic Hospital. 
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Aim. To determine changes in adherence to antiretroviral 
therapy (ART) in HIV-positive patients with depression, 
following treatment with an antidepressant or psychotherapy. 
Methods. The study was prospective, randomised and 
controlled. Consenting volunteers aged ≥18 years and 
stable on ART for ≥6 months were included in the study. 
Sociodemographic data were obtained, and a clinical 
diagnostic evaluation and the Hamilton Depression rating 
scale (HAMD) were performed on all subjects at entry 
to and at the end of the study. Participants found to be 
depressed were randomly assigned antidepressant treatment 
(20 mg citalopram) or interpersonal psychotherapy (IPT) 
(5 sessions). Medication was dispensed at each visit and 
patients were asked to return all unused medication to 
determine ART adherence. The study was approved by the 
University of the Witwatersrand. 
Results. Sixty-two HIV-positive persons receiving ART 
participated; 30 were not depressed (control group) and 32 
were depressed (patient group). No significant differences 
in demographic characteristics existed between the control 
and patient groups. Mean ART adherence at the start of 
the study was 99.5% (standard error (SE) ±0.46) and 92.1% 
(SE ±1.69) in the control and patients groups, respectively. 
Mean ART adherence at the end of the study changed 
marginally in the control group (99.7%; SE ±0.46) and 
increased significantly in the patient group (99.5%; SE± 
0.13) (p>0.05). The mean ART adherence rate of patients 
who received pharmacotherapy increased from 92.8% to 
99.5%, and of those who received psychotherapy increased 
from 91.1% to 99.6% (p>0.05). There was no significant 
association between the increased adherence in the patient 
group and baseline demographic and clinical characteristics, 
irrespective of antidepressant therapy or IPT (p>0.05). 
Conclusion. Successful treatment of depression with 
an antidepressant or psychotherapy was associated with 
improved ART adherence, independent of the type of 
treatment and sociodemographic factors. It is necessary 
to identify HIV-positive patients at risk of depression, to 
initiate antidepressant treatment which may prevent ART 
non-adherence, and subsequent disease progression and 
increased morbidity.
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The PHRU receives referrals from antenatal 
clinics for patients who test HIV-positive, 
and their partners, for initiation of ART. The 
primary objective was to determine whether 
any changes in ART adherence resulted 
following treatment with an antidepressant or 
interpersonal psychotherapy (IPT). 
Methods
The study was prospective, randomised and 
controlled, and sampling was convenience 
sampling (as it included patients attending 
the HIV clinic). Volunteers aged ≥18 years 
were included in the study. All patients were 
stable on ART for at least 6 months to reduce 
any confounding effects of the ART on mood 
and immunity. Subjects were excluded if they: 
met the Diagnostic and Statistical Manual of 
Mental Disorders (4th ed.) (DSM-IV) criteria 
for any other psychotic, mood or substance 
abuse disorder; were pregnant or nursing; or 
were medically ill (HIV wasting syndrome, or 
onset of new opportunistic infections within 
the preceding 6 weeks). Sociodemographic 
data were obtained at entry to the study. A 
clinical diagnostic evaluation and the Hamilton 
Depression rating scale (HAMD) were 
performed on all subjects at entry to and end of 
the study. The depressed patients were randomly 
assigned to receive either an antidepressant 
(10 - 20 mg/day citalopram) or IPT. Five IPT 
sessions were administered during the study 
period according to the Comprehensive Guide to 
Interpersonal Psychotherapy.41 These guidelines 
are clear, easily digested, highly informative, and 
illustrate the application of a conceptual model 
in the treatment of depression. While we were 
not trained or experienced in conducting IPT, 
it is our opinion that the therapy was correctly 
administered according to the aforementioned 
guidelines; there were, however, no objective 
measures to ensure this, signalling a limitation 
of our study. Adherence was determined by 
using the patient self-report (number of doses 
missed in the preceding 3 days) and the pill 
count (medication was dispensed at each 
visit and patients were asked to return all 
unused medication, which was counted by the 
investigator).
All participants gave written informed 
consent to participate. The study was approved 
by the Committee for Research on Human 
Subjects, University of the Witwatersrand. In 
addition to their regular follow-up visits, patients 
were required to make 2 other visits for which 
they received financial assistance for travel costs. 
ART and antidepressant drugs were supplied by 
the district mental-health clinics. 
Descriptive statistics were computed as 
means and frequencies. The 2-sample t-test was 
used to compare continuous characteristics 
(age) between the groups. Comparisons 
of change in adherence as a response 
to treatment were made between these 2 
groups (antidepressant v. psychotherapy). 
Associations with sociodemographic variables 
were examined with the use of contingency 
tables (chi-square test with Yates correction, 
Fischer’s exact test, and odds ratios). All 
analyses were performed with Statistical 
Package for Social Sciences (SPSS) software 
(version 10.0). A p-value <0.05 was considered 
significant. 
Results
Sixty-two HIV-positive persons receiving 
ART participated in the study; 30 were 
not depressed (control group) and 32 were 
depressed (patient group). 
Sociodemographic 
characteristics
In the control group, mean age was 37.7 years 
(standard error (SE) ±1.2; range 27 - 51);  88% 
were female; 70% were single (not married, 
divorced or widowed); 70% were unemployed 
despite being able and willing to work; and 
83.3% had achieved a level of education 
between grade 8 and 12 (Table 1). All control 
patients disclosed their HIV status to a partner 
or family member. The majority (63.3%) were 
receiving ART from regimen 1a; 23% were 
receiving triomune.
In the patient group, mean age was 36.8 years 
(SE ±1.38; range 24 - 53); 90.6% were female; 
67.8% were single (not married, divorced or 
widowed); 81.3% were unemployed despite 
being able and willing to work; and 71.9% had 
achieved a level of education between grade 8 
and 12 (Table 1). All patients disclosed their 
status to a partner or family member. Half of 
the patients were receiving ART from regimen 
1a; 15.6% were receiving triomune. 
There were no significant differences 
between the control and patient groups 
(receiving pharmacotherapy or psychotherapy) 
with respect to demographic characteristics, 
namely: gender (chi2=2.045; p=0.359); marital 
status; (chi2=0.547; p=0.761); employment 
status (chi2=5.707; p=0.058); highest level of 
education (chi2=2.391; p=0.664); number of 
children (chi2=5.022; p=0.285); past history 
of depression (chi2=4.124; p=0.127); family 
history of depression (chi2=2.301; p=0.316); 
or other concurrent medication (chi2=0.779; 
p=0.677) (Table 1). 
ART adherence
At entry to the study, the mean ART adherence 
was 99.5% (SE ±0.46) in the control group, and 
92.1% (SE ±1.69) (95% confidence interval (CI) 
88.65 - 95.53) in the patient group (Fig. 1). At 
the end of the study, the mean ART adherence 
in the control group changed marginally 
to 99.7% (SE ±0.46) (Fig. 1), while in the 
patient group, the mean adherence increased 
significantly to 99.5% (SE ±0.13; CI 99.25 - 
99.78; p>0.05). The mean ART adherence rate 
of the patients receiving pharmacotherapy 
increased from 92.8% to 99.5%, and those 
receiving psychotherapy increased from 
91.1% to 99.6% (p>0.05) (Fig 2). There was no 
significant association between this increased 
adherence rates in the patient group (in 
those receiving antidepressant medication 
or IPT) and baseline demographic and 
clinical characteristics (p>0.05). There was no 
correlation between the increased adherence 
rates and changes in HAMD scores.
Discussion
First-line treatment recommended by the 
2010 South African Antiretroviral Treatment 
Guidelines42 for all new adult and adolescent 
HIV-positive patients is tenofovir, lamivudine 
and efavirenz/nevirapine (efavirenz is 
preferred for TB co-infection, and nevirapine 
is preferred for women of child-bearing 
age who are not on reliable contraception). 
Patients who fail on tenofovir-based first-line 
therapy may be changed to the second-line 
treatment of zidovudine, lamivudine and 
ritonavir. The majority of patients in this study 
were receiving ART in accordance with these 
treatment guidelines. Approximately 25% of 
patients were receiving triomune (a single-
tablet fixed-dose combination of stavudine, 
lamivudine and nevirapine) which enhances 
compliance. No significant differences existed 
between the control and test groups with 
respect to the administering of ART or other 
baseline characteristics. Hence, it is unlikely 
that any of these factors may have influenced 
the study’s outcomes.
All participants in the patient group had 
HAMD scores >15, indicative of depression. 
Depression was confirmed clinically by eliciting 
cognitive and affective symptoms that solely 
reflect mood state (i.e. anhedonia, depressed 
feelings, and feelings of worthlessness). Fifty-
three per cent of the patients had moderate 
depression (HAMD score 18 - 24) and 
44% had severe depression (HAMD scores 
≥25).43 All patients responded to treatment 
– either pharmacotherapy (citalopram) or 











psychotherapy (IPT) – as evidenced by a 
significant reduction in the mean HAMD scores 
to <7 in both groups. There was no difference 
between the type of treatment received and 
changes in mean HAMD scores. These findings 
are similar to those of other studies utilising 
pharmacotherapy39,40 and psychotherapy,43,44 
which also report that IPT was more successful 
than supportive psychotherapy in lessening 
depression in depressed HIV-positive patients 
who were not acutely ill.
At entry to this study, mean ART adherence 
of the non-depressed control group was 
99.5% – much higher than the 50 - 70% rate 
reported in other studies in different social 
and cultural settings.45-50 The higher adherence 
rate in our study may be attributed to patient 
attendance at a rollout clinic that enabled 
regular monitoring and had the staff and 
resources to support patients as adherence 
problems emerged. 
The study also found that the mean 
adherence rate, at entry to the study, among 
the depressed patient group was significantly 












Gender, n (%) chi2=2.045; p=0.359
Male 9 (14.5) 6 (20) 1 (5.3) 2 (15.4)
Female 53 (85.5) 24 (80) 18 (94.7) 11 (84.6)
Marital status, n (%) chi2=0.547; p=0.761
Single 43 (69.4) 21 (70) 14 (73.7) 8 (61.5)
Married 19 (30.6) 9 (30) 5 (26.3) 5 (38.5)
Employment status, n (%) chi2=5.707; p=0.058
Employed 15 (24.2) 9 (30) 1 (5.3) 5 (38.5)
Unemployed 47 (75.8) 21 (70) 17 (94.7) 12 (61.5)
Level of education, n (%) chi2=2.391; p=0.664
Grade 0 - 7 5 (8.1) 2 (6.7) 1 (5.2) 2 (15.4)
Grade 8 - 12 48 (77.4) 25 (83.3) 14 (73.7) 9 (69.2)
Tertiary 9 (14.5) 3 (10) 4 (21.1) 2 (15.4)
Number of children, n (%) chi2=5.022; p=0.285
0 - 1 23 (37.1) 13 (43.3) 7 (36.8) 3 (23.1)
>1 39 (62.9) 17 (56.7) 12 (63.2) 10 (76.9)
PH of depression, n (%) chi2=4.124; p=0.127
Yes 4 (6.5) 1 (3.3) 3 (9.4) 0 (0)
No 58 (93.5) 29 (96.7) 16 (84.2) 13 (100)
FH of depression, n (%) chi2=2.301; p=0.316
Yes 1 (1.6) 0 (0) 1 (5.3) 0 (0)
No 61 (98.4) 30 (100) 18 (94.7) 13 (100)
ART chi2=15.68; p=0.047
Regimen 1° 35 (56.5) 19 (63.3) 7 (36.8) 9 (69.2)
Regimen 1b 8 (12.9) 1 (3.3) 5 (26.3) 2 (15.4)
Triomune 12 (17.9) 7 (23.3) 4 (21.1) 1 (7.7)
Other regimens 7 (12.7) 3 (10) 3 (15.8) 1 (7.7)
On other medication chi2=0.779; p=0.677
Yes 54 (87.1) 26 (86.7) 17 (89.5) 11 (84.6)
No 8 (12.9) 4 (113.3) 2 (10.5) 2 (15.4)







lower (92.1%) than that of non-depressed control group. As previously 
discussed, studies have reported that depression is a risk factor for 
non-adherence to highly active ART.32-35 Depression is associated 
with a passive36 or fatalistic-resigned coping style and hopelessness37 
with resultant poor treatment adherence. This study adds support to 
the findings of the above studies. Furthermore, following 2 months 
of treatment, the mean adherence rate of the depressed patients 
increased significantly to >99%, independent of the type of treatment 
received (pharmacotherapy or psychotherapy). Other published 
studies have reported similar improved ART adherence in depressed 
HIV-positive patients following treatment with an antidepressant or 
IPT.5,51 When medication is used to treat depression, it is important 
for clinicians to evaluate tolerability and potential adverse effects 
which may paradoxically decrease adherence.52 Selective serotonin 
reuptake inhibitors (SSRIs) have become widely used in HIV-infected 
depressed patients because of good tolerability and lack of negative 
effect on adherence. If, however, adherence is negatively impacted 
by pharmacotherapy, IPT may be the preferred treatment choice, as 
it results in increased physical and emotional functioning without 
tolerability issues. Finally, a combination of both forms of therapy 
may result in further improved outcomes.
Some researchers question the feasibility of the rapid scaling-up 
and sustainability of ART programmes in depressed people,25,53 citing 
concerns about the low and suboptimal adherence in depressed patients 
leading to the development of resistant HIV strains.54-56 Resistant strains 
may leave subsequently infected patients without effective treatment 
options24 or require a change to second-line treatment regimens, 
which are ten times more expensive than first-line regimens.57 On the 
contrary, the results of our study and others have shown that the onset 
of depression in HIV-positive patients is negatively associated with 
ART adherence, and can be significantly improved with treatment. 
Screening for depression in all ART rollout clinics is essential and 
HIV-positive patients found to be depressed must be offered ART and 
treatment for their depression. 
Although not considered or evident in our study, many other 
factors have been reported to negatively affect ART adherence. 
These factors are commonly divided into 5 intersecting categories: 
patient variables; treatment regimens; disease characteristics; patient-
provider relationships; and clinical setting.59 Patient variables include 
sociodemographic factors (age, gender, race, income, education, 
literacy and housing status) and psychosocial factors (mental health, 
substance abuse, family support, religious beliefs about illness 
and medication, and knowledge and attitude about HIV and its 
treatment).58-67 Studies investigating the role of patient variables as 
predictors of adherence have largely produced inconsistent results. 
The tendency to ascribe low adherence to often-deprived social groups 
is a well-established trend;68 however, as experience with antibiotics 
has demonstrated, low adherence is widespread and unpredictable 
rather than restricted to certain social classes.69 Moreover, adherence 
rates have been shown to vary between individuals and within the 
same individual over time.59 
Adherence is therefore best thought of as a variable behaviour rather 
than a stable characteristic of an individual, and most people will exhibit 
low adherence some of the time.68 Treatment regimen factors include 
the number of pills prescribed, the complexity of the regimen (dosing 
frequency and food instruction), the specific type of ART and treatment 
side-effects. The latter two are associated with sub-optimal adherence,58 
although experience of symptoms and views about medications may vary 
according to the type of regimen used.70-72 Patient-provider relationship 
factors include: overall satisfaction and trust in the provider and clinic 
staff (opinion of the provider’s competency, provider’s willingness to 
include the patient in the decision-making process, and compatibility 
of race/ethnicity between patient and provider); affective tone of the 
relationship (warmth, openness and co-operation); and satisfaction with 
the health service (adequacy of referral, availability of transport, general 
environment and flexibility of appointments).73
Methods used to asses adherence fall into 3 categories: subjective 
measures (self-report, others’ report of adherence, and medical chart 
review); objective measures (pill counts, pharmacy refill records, and 
use of mechanical or electronic monitors of pill or drug use); and 
physiological methods or indicators (plasma assay and laboratory 
reports).15 The hierarchy of adherence measures ranks physician 
and self-assessment reporting as the least accurate, pill count as 
intermediate and electronic drug monitoring as the most accurate 
adherence markers.25 Each of these measures is associated with certain 
inaccuracies and implementation difficulties. Pharmacy refill records 
require that patients always use the same pharmacy. Pill counts require 
patient co-operation to bring their pills to the requested health visits, 
and not to share pills. The medication event-monitoring system 
(MEMS) allows recording of when a drug container is opened via a 
micro-processor in the cap of the container. However, this requires that 
patients only remove one dose at a time. Moreover, caps only measure 
bottle opening and not medication ingestion. The pill count method 
Fig. 2. Changes in ART adherence in the antidepressant v. IPT groups. 
Fig. 1. Changes in ART adherence in the control and patient groups.











may overestimate adherence compared 
with MEMS by about 10%,48,74 but still has a 
higher accuracy compared with structured 
questionnaires.75 
The subjective measure of patient self-
report is the most commonly used measure 
of adherence. In this measure the patient is 
asked how many doses were missed in the 
past day, 2 days and 2 weeks or, alternatively, 
the percentage of prescribed doses taken in 
the past 4 days.47 The format of the questions 
varies from study to study. Using this 
measure, inaccuracies may result from use of 
a longer recall time, in patient forgetfulness 
and when questioning is imprecise or 
inconsistent. Further, responses may be 
influenced by patients’ desire to provide a 
socially acceptable answer, particularly when 
the interviewer is a health worker whose role 
has been to exhort the patient to adhere. 
Nevertheless, self-reported adherence 
questionnaires are simple and inexpensive 
and the most widely used method in clinical 
settings.29,30 No single measure of adherence 
is appropriate for all settings or outcomes; 
therefore, the use of more than one measure 
is recommended, as performed in this study, 
to allow the strength of one method to 
compensate for the weakness of the other 
and to determine adherence levels more 
accurately.76
Study limitations
The relatively small sample size might have 
hampered statistical comparisons between 
treatment groups, while the short duration 
of follow-up might have masked a greater 
degree of outcomes in both groups. The 
study was open-labelled, which could have 
influenced the response to treatment. This 
was not a population-based study (patients 
were recruited from the HIV Research Unit); 
therefore, the results may be biased by the 
methods of recruitment and enrolment and are 
not generalisable. Further, an overwhelming 
majority of the subjects were female; the 
treatment of HIV-positive men, who face 
different psychosocial and socio-economic 
pressures, may have produced different 
outcomes. 
Strengths of the study include the use of 
more than one adherence measure to reduce 
inaccuracies. Moreover, comparison of the 
sociodemographic characteristics did not 
reveal any substantive differences between 
the groups.
Conclusion
The onset of depression in HIV-positive 
patients is negatively associated with ART 
adherence. Treatment of this depression 
with an antidepressant or psychotherapy is 
associated with significant improvement in 
ART adherence. Poor adherence leads to 
ART resistance, which may require a change 
to a second-line treatment regimen (ten 
times more expensive than first-line drugs). 
It is therefore important that healthcare 
providers identify depression in at-risk 
patients, to enable closer monitoring and 
treatment. 
Note. This report was part of a large study on 
HIV and depression. The sociodemographic 
features of the study population described 
have previously been reported: 
Moosa MYH, Jeenah FY. Antidepressants versus 
interpersonal psychotherapy in treating depression 
in HIV-positive patients. South African Journal of 
Psychiatry 2012;18(2) 47-52.
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